Close Menu

NEW YORK (GenomeWeb) – After Aevi Genomic Medicine recently reported that a trial investigating a personalized drug for attention deficit hyperactivity disorder, AEVI-001, failed to meet its primary endpoint, the company has performed an additional analysis in an effort to better define predictive markers and home in on the subpopulation of adolescents most likely to benefit from therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.

NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.

ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.

In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.